FDA Brief

Warning letters Drugs

FDA warning letter to

QuVa Pharma, Inc.

Issued Jan 26, 2024Posted Feb 13, 2024Division of Pharmaceutical Quality Operations I

Compounding Pharmacy/Adulterated Drug Products. We haven't summarized this letter yet. Read it on fda.gov.

QuVa Pharma, Inc.'s FDA history

Recalls in the last 12 months

Jul 15 Class II QuVa Pharma, Inc.
Drug
Methohexital Sodium, 100 mg/10 mL (10 mg/mL), Total Volume: 10 mL, Rx only, Compounded drug, QuVa Pharma, 1075 W Park One Dr, Suite 100, Sugar Land, TX 77478, Product code: 70092-1310-46.
Failed Impurities/Degradation Specifications

Full company page